ECSA/DPPA2 is an Embryo-Cancer Antigen that Is Coexpressed with Cancer-Testis Antigens in Non–Small Cell Lung Cancer
Purpose: Cancer cells recapitulate many behaviors of pluripotent embryonic cells such as unlimited proliferation, and the capacity to self-renew and to migrate. Embryo-cancer sequence A ( ECSA ), later named developmental pluripotency associated-2 ( DPPA2 ), is an embryonic gene initially isolated f...
Saved in:
Published in: | Clinical cancer research Vol. 14; no. 11; pp. 3291 - 3298 |
---|---|
Main Authors: | , , , , , , , , , , , , , , , |
Format: | Journal Article |
Language: | English |
Published: |
Philadelphia, PA
American Association for Cancer Research
01-06-2008
|
Subjects: | |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Summary: | Purpose: Cancer cells recapitulate many behaviors of pluripotent embryonic cells such as unlimited proliferation, and the capacity
to self-renew and to migrate. Embryo-cancer sequence A ( ECSA ), later named developmental pluripotency associated-2 ( DPPA2 ), is an embryonic gene initially isolated from pluripotent human preimplantation embryos. We hypothesized that ECSA/DPPA2
would be quiescent in most normal tissues but expressed in cancers and may therefore be a useful target for immunotherapy.
Experimental Design: ECSA/DPPA 2 expression was examined in a panel of normal and tumor tissue by reverse transcription PCR, quantitative real-time PCR,
and immunohistochemistry. A panel of 110 non–small cell lung cancers (NSCLC) were further investigated for the presence of
ECSA/DPPA2 transcripts and several cancer testis antigens (CTA). Sera from 104 patients were analyzed for spontaneous ECSA/DPPA2 antibody production by ELISA and Western blot.
Results: ECSA/DPPA 2 transcripts were limited to normal testis, placenta, bone marrow, thymus, and kidney but expressed in a variety of tumors
most notably in 30% of NSCLC. Enrichment for CTAs in ECSA/DPPA2 -positive NSCLC was observed. Immunohistochemistry confirmed nuclear and cytoplasmic localization in subpopulations of cells
with coexpression of the CTA MAGE-A3. Antibodies to recombinant ECSA/DPPA2 protein were detected in the sera of 4 of 104 patients
with NSCLC but not in healthy controls.
Conclusions: The restricted expression in normal tissues, expression in tumors with coexpression of CTAs, and spontaneous immunogenicity
indicate that ECSA/DPPA 2 is a promising target for antigen-specific immunotherapy in NSCLC. |
---|---|
Bibliography: | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
ISSN: | 1078-0432 1557-3265 |
DOI: | 10.1158/1078-0432.CCR-07-1322 |